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A Novel Fluorescence Resonance Energy Transfer-Based Screen in
High-Throughput Format To Identify Inhibitors of Malarial and
Human Glucose Transporters
Department of Pediatrics,a Department of Molecular Microbiology,d Department of Cell Biology and Physiology,e and High Throughput Screening Core,b Washington
University School of Medicine, St. Louis, Missouri, USA; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota,
USAc

The glucose transporter PfHT is essential to the survival of the malaria parasite Plasmodium falciparum and has been shown to
be a druggable target with high potential for pharmacological intervention. Identification of compounds against novel drug targets is crucial to combating resistance against current therapeutics. Here, we describe the development of a cell-based assay system readily adaptable to high-throughput screening that directly measures compound effects on PfHT-mediated glucose transport. Intracellular glucose concentrations are detected using a genetically encoded fluorescence resonance energy transfer
(FRET)-based glucose sensor. This allows assessment of the ability of small molecules to inhibit glucose uptake with high accuracy (Z= factor of >0.8), thereby eliminating the need for radiolabeled substrates. Furthermore, we have adapted this assay to
counterscreen PfHT hits against the human orthologues GLUT1, -2, -3, and -4. We report the identification of several hits after
screening the Medicines for Malaria Venture (MMV) Malaria Box, a library of 400 compounds known to inhibit erythrocytic
development of P. falciparum. Hit compounds were characterized by determining the half-maximal inhibitory concentration
(IC50) for the uptake of radiolabeled glucose into isolated P. falciparum parasites. One of our hits, compound MMV009085,
shows high potency and orthologue selectivity, thereby successfully validating our assay for antimalarial screening.

M

alaria is a major threat to the human population in large
areas of the world, affecting over 200 million people per year
(1, 2). Beyond the effects of this disease on human life, malaria also
cripples economic development and burdens the health care systems of countries where malaria is endemic (3). The emergence of
parasites with resistance to even the most potent existing antimalarial drugs, such as the artemisinins (4), has made paramount the
development of novel drugs that target essential pathways for parasite survival. Blood stage parasites utilize glucose for both biomass production and ATP synthesis (5). The malarial hexose
transporter, Plasmodium falciparum hexose transporter (PfHT),
first cloned by Woodrow et al. in 1999 (6), mediates parasite transport of glucose, fructose, mannose, and galactose (7). Since PfHT
is essential for parasite survival (8), this protein is a highly promising molecular target for antimalarial drug development. This is
supported by the ability of compound 3361, a glucose analogue
that inhibits PfHT with high selectivity over the human orthologue GLUT1, to inhibit asexual intraerythrocytic growth in culture (9). Compound 3361 is also active against Plasmodium berghei liver and transmission stage parasites in infected mice (10),
suggesting that PfHT is a promising target for full life cycle activity. However, while compound 3361 validates efforts to target
PfHT, this compound is not itself considered drug-like and is
therefore not a valid candidate for lead development (11). We
have recently extended these earlier findings by identifying PfHT
as a molecular target of the HIV protease inhibitor lopinavir, thus
providing a link between lopinavir use and decreased malarial
transmission in areas where HIV and malaria are both endemic
(12). However, lopinavir has a relatively high half-maximal inhibitory concentration (IC50), 16 M, in parasites and shows higher
selectivity for the human insulin-responsive glucose transporter
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GLUT4 over PfHT (12). Therefore, novel therapeutics targeting
PfHT with improved potency and selectivity are required.
The development of a robust and efficient high-throughput
screening assay to identify novel PfHT inhibitors requires consideration of simplicity, sensitivity, scalability, cost, and reliability.
Current assays for transporter inhibition in a high-throughput
format generally employ radiolabeled substrate or cell death of a
transporter-overexpressing cell line as a readout (13, 14). Both
formats have significant limitations. Although measuring the uptake of radiolabeled substrate generally yields quantitative, highly
reproducible results, the use and disposal of radiolabels are expensive and handling radioactive substances requires increased safety
precautions. Alternatively, using cell death of an engineered cell
line that requires transporter function for survival is an elegant
way to simplify the readout. In both cases, these assays fail to
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TABLE 1 Human glucose transporter primers for qPCR
Forward primer sequence

Reverse primer sequence

Amplicon size (bp)

GLUT1
GLUT2
GLUT3
GLUT4
GLUT5
GLUT6
GLUT7
GLUT8
GLUT9
GLUT10
GLUT11
GLUT12

AACTCTTCAGCCAGGGTCCAC
TTTCAGGCCTGGTTCCTATG
ACTTTGACGGACAAGGGAAATG
CATGCTGGTCAACAATGTCC
GTCGGCCCCTTGGTGAATAA
GGCTGCTCATGTCTGAGGTC
TGCAGGCATCTCCTACAGC
CCATCTTTGAAGAGGCCAAG
TGGCAAAGATCCCATACGTC
GCTGTCCTGCAATCCCTCAG
GGAGTCAATGCAGGTGTGAG
TGCTGGATTAAGCCACACTG

CACAGTGAAGATGATGAAGAC
GATGGCCAGCTGATGAAAAG
ACCAGTGACAGCCAACAGG
CCAATGAGGAATCGTCCAAG
AATGATGTGGCGACTCTGCT
GATGGCCGCGAAGAAGAAGAA
ACGAAAACCTCGGTCATTGTTC
ATGACCACACCTGACAAGACC
AGGTGCTCAATGACCAAACC
GTCCGGCCTCGCATGTTATC
CCAGAGCCGTAAAGATGGCTG
TGGCTAAGGACAGCCATTTC

140
86
180
105
110
161
96
145
85
173
112
83

discriminate between compounds that kill the cells through transporter inhibition and compounds that kill through other mechanisms, resulting in false-positive rates as high as 97.8% (15). Here,
we report the development and validation of a novel assay for
determination of compounds that efficiently and selectively block
PfHT.
MATERIALS AND METHODS
Materials. [14C]2-deoxyglucose (2-DOG) and [3H]2-DOG were purchased from American Radiolabels Inc. GLUT1 short hairpin RNA
(shRNA) was obtained through the RNA interference (RNAi) core at
Washington University School of Medicine. HEK293 cells were acquired
from the American Type Culture Collection (ATCC). Lopinavir was obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH.
HEK293 cell line generation. HEK293 cells were transfected with
pcDNA3.1 FLII12Pglu-700␦6 (Addgene), containing the fluorescence
resonance energy transfer (FRET) glucose sensor (HEK293-FLIP), using
Optifect reagent (Life Technologies) according to the manufacturer’s
specifications. Cells that stably integrated the gene were selected using
G418 (Sigma-Aldrich), and the highest expressers were identified using
fluorescence-activated cell sorting (FACS). These cells were then stably
transfected with PfHT, human GLUT1 (hGLUT1), hGLUT2, hGLUT3, or
hGLUT4 DNA in the pcDNA 3.1(⫺) hygro plasmid (Life Technologies)
as described previously (12). Single clones were selected by comparing
their abilities to transport radiolabeled glucose. In all cell lines except for
HEK293 cells overexpressing hGLUT1, native hGLUT1 was knocked
down using shRNA as described elsewhere (12). PfHT expression levels in
overexpressing cells were previously characterized (12).
RNA isolation and qPCR. To quantify mRNA transcript levels in the
four GLUT-overexpressing cell lines, total RNA was isolated using the
TrizolW Plus RNA purification system (Invitrogen), and 1 g of RNA was
reverse transcribed using qScript cDNA Supermix (Quanta Biosciences).
Quantitative reverse transcription-PCR (qRT-PCR) was performed using
Power SYBR green PCR master mix (Applied Biosystems). Each reaction
was run in triplicate using the primers listed in Table 1. Quantifications
were performed with standard curves generated using plasmids containing each human GLUT (DNASU).
Assay optimization and high-throughput screening. Several conditions were optimized to increase the sensitivity and reliability of the assay.
Ninety-six-well plates were pretreated with 25 g/ml of polyethylenimine
(PEI; 750 kDa; Sigma-Aldrich) solution containing 150 mM NaCl to
maintain cell adhesion during washing steps. After 20 min of incubation
at room temperature, PEI was aspirated and wells were air dried for 5 min.
PfHT-FLIP cells were plated 48 h prior to the assay in black opaque 96well plates (Greiner Bio-One), which had been previously treated with
PEI, at 30,000 cells/well. After cell plating, plates were left in the sterile
hood at room temperature for 45 min before transfer to the incubator to
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reduce edge effects. Compound screening was performed using the integrated and automated screening system (Beckman Coulter) at the Washington University High Throughput Screening Core. We used SAMI EX
software (Beckman Coulter) to design and execute the screening protocol.
The Malaria Box (Medicines for Malaria Venture [MMV]) compound
library was prediluted in glucose-free HEPES-buffered saline solution
(HBSS) (146 mM NaCl, 4.7 mM KCl, 0.6 mM MgSO4, 1.6 mM NaHCO3,
0.13 mM NaH2PO4, 2.5 mM CaCl2, 20 mM HEPES [pH 7.3]) using a
BiomekFX liquid handler (Beckman Coulter). We prepared a 1:100 dilution of 1 mM stock solution for a 10 M final concentration.
To initiate the screening assay, cells were washed twice with 150 l of
HBSS per well using an ELx405 plate washer (Biotek). Cells were starved
in HBSS for 30 min at room temperature, followed by aspiration of the
HBSS from cell plates using the ELx405 plate washer. Cells were treated
with 45 l of diluted compound using the BiomekFX (with 3 replicate cell
plates for each library plate) and incubated for 6 min at room temperature. To initiate the uptake, 5 l of 100 mM glucose was added to the wells
(final concentration, 10 mM) using a Multidrop384 dispenser (Thermo
Fisher Scientific). After incubation at room temperature for 120 min,
fluorescence was measured using a 2102 EnVision multilabel plate reader
(PerkinElmer) at an excitation wavelength of 436 nm (cyan fluorescent
protein [CFP]) and emission wavelengths of 485 nm (CFP) and 535 nm
(yellow fluorescent protein [YFP]).
P. falciparum culture. P. falciparum strain 3D7 was obtained from the
Malaria Research and Reference Reagent Resource Center (MR4). P. falciparum parasites were cultured in a 2% suspension of human erythrocytes and RPMI 1640 medium (Sigma-Aldrich) supplemented with 27
mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium
pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 g/ml of gentamicin, and 0.5% Albumax (Gibco) at 37°C in a 5% O2–5% CO2–90% N2
atmosphere as previously described (16, 17).
P. falciparum growth inhibition assays. Asynchronous P. falciparum
cultures were diluted to 1% parasitemia and were treated with compounds at concentrations ranging from 9.8 nM to 20 M. Growth inhibition assays were performed in 100-l cultures in opaque 96-well plates.
Parasite growth was quantified after 3 days by measuring DNA content
using PicoGreen (Life Technologies) (18). Fluorescence was measured by
a FLUOstar Omega microplate reader (BMG Labtech) at a 485-nm excitation wavelength and a 528-nm emission wavelength. IC50s were calculated by nonlinear regression analysis using GraphPad Prism software.
Measurements of radiolabeled glucose uptake. P. falciparum strain
3D7 was cultured in 100-mm tissue culture dishes (Techno Plastic Products) in a 2% suspension of human erythrocytes and RPMI 1640 medium
until reaching ⬎5% parasitemia. Cells were pelleted via centrifugation
and resuspended in RPMI 1640 medium. In order to determine the uptake of radiolabeled glucose into the parasite, we isolated it from the erythrocytes while removing uninfected erythrocytes as described in references
19 and 20. Uptake of [14C]2-DOG into isolated parasites was determined
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at room temperature using the methods described previously (19). Test
compounds were added 5 min prior to the addition of [14C]2-DOG (0.2Ci/ml final concentration). Uptake was quenched after 2 min. Data were
fit by nonlinear regression analysis using GraphPad Prism software. Uptake of [3H]2-DOG into HEK293-FLIP cells was measured in HEPESbuffered saline at room temperature for 4 min as described previously
(20). Data were fit by nonlinear regression analysis using GraphPad Prism
software.

RESULTS

Assay development and optimization. The ideal PfHT assay
would evaluate transporter function as a direct, highly reproducible readout without the use of radiolabels. We therefore designed
a cell line that transports glucose almost exclusively through PfHT
and combined this with an intracellular glucose sensor protein
that translates glucose concentration into a fluorescence signal as
a readout. We used the glucose sensor FLII12Pglu-700␦6 (FLIP),
initially developed and characterized in the laboratory of Wolf
Frommer, to qualitatively assess cellular glucose influx (21). This
genetically encoded optical glucose sensor consists of three protein domains: a central glucose-binding domain that is coupled
terminally to a CFP and a YFP. Upon excitation of CFP, energy is
transferred to YFP through FRET. When glucose enters the cell, it
binds to the glucose binding domain, leading to a conformational
change that brings the two fluorescent proteins closer together
and increases FRET (Fig. 1). Using the human embryonic kidney
cell line HEK293, we created a reporter cell line stably expressing
PfHT in conjunction with FLIP (PfHT-FLIP cells). HEK293 cells
are known to exhibit relatively low endogenous glucose uptake
(21). To further reduce background levels of glucose uptake, we
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FIG 2 (a) Time-dependent change in FRET ratio (YFP emission/CFP emission) after addition of glucose to PfHT-FLIP cells in the presence or absence of
lopinavir. (b) Time-dependent change in FRET ratio after addition of glucose
to PfHT-FLIP cells in the presence or absence of cytochalasin B (CB).

knocked down the primary endogenous transporter isoform
GLUT1 using shRNA, yielding a cell line that predominantly
transports glucose through PfHT (12). We tested the function of
our engineered cell line by measuring the time course of glucose
uptake via readout of the YFP/CFP ratio (FRET ratio) in the presence and absence of known PfHT inhibitors. In the presence of the
HIV protease inhibitor lopinavir (Fig. 2a), previously identified to
block PfHT-mediated glucose uptake, PfHT-FLIP cells showed a
decreased FRET ratio with addition of D-glucose, consistent with
inhibition of radiolabeled D-glucose uptake in these cells (12).
Additionally, we confirmed concentration-dependent inhibition
of glucose uptake in PfHT-FLIP cells by the glucose transport
inhibitor cytochalasin B (CB) as previously shown in Xenopus
laevis oocytes (6). In PfHT-FLIP cells, CB causes a maximal decrease in FRET ratio of 75% at 50 M, consistent with radiolabeled uptake inhibition in oocytes (6) and complete inhibition of
D-glucose uptake at 200 M (Fig. 2b). CB is therefore an ideal
positive control for assay optimization and high-throughput
screening.
We optimized the assay for high-throughput application in a
96-well format using the Z= factor and the coefficient of variation
(CV) as measures of assay robustness (22). For these measurements, half of the plate was treated with 200 M CB as a positive
control and the other half with a vehicle prior to the addition of
D-glucose. Cells adhered tightly to the plate bottom after treatment of the plate with the highly branched polymer PEI, which
acted as an adhesive, thereby preventing cells from dislodging during washing and buffer exchange steps. After optimization of assay
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FIG 1 (a) Generation of cell lines for high-throughput screening. HEK293
cells were stably transfected with the P. falciparum hexose transporter (PfHT)
and the glucose sensor FLII1212Pglu-700␦6 and treated with small interfering RNA (siRNA) directed at hGLUT1 to reduce background glucose uptake.
(b) Glucose FRET sensor expressed in PfHT-expressing cells. In the absence of
glucose, CFP and YFP are further apart and the amount of energy transferred
from the donor CFP to the acceptor YFP that is emitted as light (FRET signal)
is low (figure adapted from reference 21; used with permission). Glucose binding to the glucose/galactose binding domain (MgIB) leads to a conformational
change that brings CFP and YFP closer together, resulting in an increased
FRET signal.

Kraft et al.

CB (inhibitor) and 48 wells treated with a vehicle. Z= factor and the coefficient
of variation (CV) were determined from the average and SD of each set of wells
according to reference 20.

temperature, fluorescence read mode, cell density, and cell
plating protocol, we were able to routinely obtain a Z= factor of
⬎0.8 (a perfect assay would have a Z= factor of 1.0) and a CV of
⬃2% (Fig. 3).
Screening of the Malaria Box compound library. In order to
test our assay conditions in an automated setting for highthroughput application, we selected the MMV Malaria Box, a
small library of 400 compounds previously shown to have a cytotoxic effect on malaria parasites (23). This library contains chemically diverse compounds, with half of the compounds having
drug-like properties and the other half having been selected as
molecular probes. As this compound set was selected for their
cytotoxic activity against blood stage malaria parasites, the molecular drug targets remain to be determined. The rationale for
choosing this library was to identify compounds that inhibit parasite growth mainly or partially through blockade of PfHT-mediated glucose uptake, since deorphanization of these compounds
(i.e., identification of the direct molecular targets of anti-antimalarial action) will aid in further target-directed drug development.
We screened the Malaria Box at 10 M drug concentrations in
TABLE 2 Comparison of hit IC50s for different assaysa

Compound ID

Heterologous screening assay
(% inhibition at 10 M)

IC50 for glucose
uptake in freed
parasites

EC50 for growth
inhibition of P.
falciparum 3D7

EC50 for P. falciparum
growth inhibition,
Malaria Box

IC50 for
L. mexicana

MMV020548
MMV665941
MMV009085
MMV000326
MMV665879
MMV665898

21
31
87
49
49
64

15.5
19.6
2.6
286
8.3
5.3

0.114
0.026
0.987
0.344
0.390
0.487

0.361
0.255
0.795
1.170
ND
1.220

3.5
ND
0.051
ND
2.7
ND

a
IC50s for glucose uptake in freed parasites were determined from dose-response curves shown in Fig. 4. IC50s for inhibition of growth of P. falciparum strain 3D7 intraerythrocytic
forms by each compound were determined via a growth inhibition assays as described in Materials and Methods. Half-maximal effective concentrations (EC50s) provided with the
malaria box and IC50 values determined by Ortiz et al. (15) for inhibition of glucose uptake into PfHT-overexpressing L. mexicana parasites are also tabulated. ID, identifier; ND,
not determined.
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FIG 3 FRET ratio per well of a 96-well plate, with 48 wells treated with 200 M

triplicate and selected hits that decrease the FRET ratio by more
than 30% with vehicle-treated cells set to 100% and cells treated
with 200 M CB set to 0%. Since fluorescent compounds have the
potential to generate false-positive hits, the FRET ratio of compounds without cells present was determined. After false-positive
elimination, we identified 5 compounds as primary hits. Hit confirmation was ascertained by determining the IC50 for glucose
uptake into isolated P. falciparum parasites from blood culture
using radiolabeled D-glucose. Four of the five primary hits could
be confirmed to inhibit glucose uptake into P. falciparum parasites in the low micromolar range (Table 2), with compound
MMV665941 showing only partial inhibition at the highest concentration tested (Fig. 4). We included compound MMV020548
for comparison as it was previously identified by Ortiz et al. (15)
from the same library. The similar IC50 observed in the free-parasite glucose uptake assay and in vitro growth inhibition assay for
MMV009085 (23) is consistent with the interpretation that this
compound acts through PfHT blockage to inhibit parasite growth
(Table 2), although alternative targets in the parasite might be
inhibited as well. Since the measurement of 2-DOG uptake involves both the transport of this sugar and phosphorylation to
2-DOG-6-phosphate (2-DOG-6-P), we cannot fully exclude the
possibility that the identified compounds also inhibit the malarial
hexokinase. However, the observations that they inhibit 2-DOG
uptake with different potencies and that compound MMV009085
shows a widely different IC50 when measured in HEK293 cells
overexpressing different GLUTs (see Fig. 6) suggest that hexokinase is not directly targeted.
To establish selectivity of these hits for PfHT over human orthologues, we cross-validated the inhibition of GLUT1, -2, -3, and
-4 by the confirmed hits. Using the same HEK293-FLIP cell line,
we overexpressed each of the individual class I transporters. With
the exception of GLUT1-FLIP, the other GLUT cell lines were also
treated with GLUT1-specific shRNA to reduce background glucose uptake. We confirmed that the overexpressed GLUT was the
main glucose transporter expressed in each cell line by comparing
the cDNA copy number of all human SLC2A genes via qPCR (Fig.
5). Total transcript numbers differed between various GLUT isoform-overexpressing cell lines as the construct was integrated randomly into the genome of the host cell as discussed in Materials
and Methods. We determined the inhibitory effects of the five
confirmed hits on all four human class I GLUTs at the IC50 for
PfHT-mediated glucose uptake inhibition. Only compound
MMV009085, the most potent hit, with an IC50 of 2.6 M for

Glucose Transporter FRET Screen

intracellular concentration of radiolabel relative to the extracellular concentration) were calculated as described previously (14). IC50s were calculated using
nonlinear regression analysis and are tabulated in Table 2. Uptake data are expressed as means ⫾ SEMs (n ⫽ 3). Chemical structures of the compounds tested are
shown for comparison.

PfHT-mediated glucose uptake, showed significantly less inhibition of the human GLUTs than for PfHT (Fig. 6a). Comparison of
the IC50s for glucose uptake inhibition, mediated by either the
human GLUTs or PfHT, revealed a ⬎10-fold-higher selectivity of
MMV009085 for PfHT over human orthologues (Fig. 6b). Al-

though MMV009085 is considered a probe-like molecule, its high
potency in inhibiting both glucose uptake and growth of the parasites as well as its high selectivity for PfHT over human orthologues makes this compound a potential candidate for lead optimization. Additionally, it demonstrates that our newly developed

FIG 5 Copies of transcript per nanogram of cDNA for each glucose transporter SLC2A family member in HEK293-FLIP cells overexpressing (OE) hGLUT1 (a),
hGLUT2 (b), hGLUT3 (c), and hGLUT4 (d) in comparison to HEK293 wild-type cells and/or HEK293 wild-type cells treated with siRNA targeting hSLC2A1
(hGLUT1 kd).
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FIG 4 Uptake of [14C]2-DOG by isolated P. falciparum trophozoites at increasing concentrations of hit compounds. Distribution ratios (i.e., the ratio of

Kraft et al.

assay can identify glucose transporter-specific inhibitors and further distinguish compounds with high selectivity for their target
over its orthologues or isoforms.
DISCUSSION

We describe here the development of a novel assay system adaptable to high-throughput screening for small molecules that inhibit
glucose uptake. The ability to identify compounds with selectivity
for the malarial glucose transporter PfHT over human GLUT
transporters provides a powerful new means to identify safe and
effective antimalarial agents. Our results show high reproducibility, with a CV of ⬃2% and good separation of hits from background, with a Z= factor of ⬎0.8, indicative of a high-quality assay
for high-throughput screening (22). Additionally, by not requiring radioactive labels, this assay increases throughput and ease of
use with substantially reduced cost. This is especially important in
the field of infectious diseases affecting people in the developing
world (24). The assay employs cells that genetically encode the glucose transporter and a glucose sensor utilizing a direct fluorescent
readout. This eliminates the need for time-consuming protein purification steps and expensive radiolabeled or fluorescently labeled substrates. Every step in our protocol was successfully tested in a fully
automated setup in order to test the true scalability to high throughput. Our initial screen of a 400-compound library resulted in four
verified hits. Although the rate of false-positive compounds identified
after the initial round of screening is significantly lower than in a
previously reported PfHT inhibitor assay (15), further improvements
can be made by selecting a higher threshold of FRET ratio reduction,
especially when screening a larger library or using different detection
methods like fluorescence lifetime (25, 26). The hits identified in this
screen include three compounds (MMV009085, MMV020548, and
MMV665879) that were previously identified and characterized
by Ortiz et al. (15) to selectively inhibit glucose uptake, but not
proline transport, in PfHT-overexpressing Leishmania mexicana.
However, the L. mexicana assay system showed noncorrelated results for the IC50 of compound MMV009085 (IC50 of 0.99 M in
the malaria parasite growth assay but 0.051 M in the L. mexicana
PfHT overexpression assay). This 20-fold difference in potency by
the two assays indicates that in the cross-expression system (PfHT
in the Leishmania parasite) MMV009085 might have an alternative target, originating from L. mexicana. In our screen, reduc-
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tion in FRET ratio correlated with inhibitory potency of the compound in the freed-parasite glucose uptake assay (R2 ⫽ 0.83,
excluding outlier MMV000326), with the most potent inhibitor,
MMV009085, showing the strongest decrease in FRET ratio.
The quality of hits in drug discovery projects is crucial in improving the odds of developing a successful candidate for clinical
application, especially as downstream investments into the hits
that are selected for lead development are significant in terms of
both funding and time (24). Therefore, target-based screens have
advantages over phenotypic screens, as they allow lead identification and optimization that are directed toward the malarial target
protein versus human orthologues. We adapted our assay system
to include counterscreening of PfHT-specific hits against human
glucose transporters. The facilitative glucose transporters GLUT1
to -4 are fundamentally important for human glucose homeostasis,
as they are primary glucose transporters in most tissues (27). PfHT
and the human transporters share a major facilitator superfamily
(MFS) fold and show a sequence similarity of close to 50%. The significance of the human GLUTs and their close homology to the malarial glucose transporter make it crucial, but potentially challenging,
to identify drugs with high parasite orthologue selectivity. By replacing PfHT with human GLUTs, our HEK293 cell-based assay system
successfully distinguished PfHT-specific from orthologue-nonspecific inhibitors and identified a compound that showed a 19- to
⬎250-fold high selectivity for PfHT over the human GLUTs.
An additional advantage of target-directed screening is the opportunity for structure-based rational drug design to aid in lead
compound optimization, particularly with respect to selectivity
for PfHT over human GLUTs. For the mammalian glucose transporters, recent progress has been made in solving the crystal structures of several isoforms in both inward and outward conformations (28–30). Furthermore, our prior work has provided
evidence for the binding pocket that mediates transporter inhibition by HIV protease inhibitors (12, 20, 31). This has been used to
model lopinavir binding to a model of PfHT (12). Taken together,
these data provide a framework for iterative structure-activity
analysis of compounds identified via our newly developed highthroughput screening assay.
In addition to selecting orthologue-specific PfHT inhibitors,
the GLUT-expressing FLIP cell lines can be used to identify
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FIG 6 Specificity of hit compounds for PfHT over human orthologues. (a) Uptake of [3H]2-DOG by HEK293 cells overexpressing hGLUT1 to hGLUT4 in the
presence of hit compounds at their IC50 for PfHT (Table 2). (b) Uptake of [3H]2-DOG by HEK293 cells overexpressing PfHT or hGLUT1 to hGLUT4 at
increasing concentrations of compound MMV009085. Uptake data are expressed as means ⫾ SEMs (n ⫽ 3). IC50s were calculated using nonlinear regression
analysis.
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GLUT-specific inhibitors with isoform selectivity with applications beyond antimalarial therapy. Several types of tumors have
been shown to overexpress specific GLUT isoforms that mediate
the transport of high levels of glucose to malignant cells that have
undergone metabolic rearrangement and primarily metabolize
glucose through aerobic glycolysis (known as the Warburg effect)
(32, 33). Many cancer cells express transporter isoforms that are
not found in these tissues under nonmalignant conditions.
Among the class 1 facilitative glucose transporters, GLUT1 is most
abundantly expressed in breast, brain, lung, colorectal, and bladder cancers (34). Inhibition of GLUT1 has already been shown to
exert antineoplastic effects both in vitro and in vivo (35, 36), making it a promising target for cancer therapy. Expression of the
glucose transporters GLUT2, GLUT3, and GLUT4 is also upregulated in various tumors, among them several types that are difficult to treat and are associated with low survival rates, like lung,
pancreatic, and liver tumors (32, 34, 37). Our cell-based, targetspecific screen is designed to be easily adaptable to mediate glucose transport through selectively expressed transporter isoforms.
This versatility combined with a robust, easily detectable readout
significantly increases the feasibility of screening large compound
libraries to identify isoform-specific GLUT inhibitors that can be
further developed into drugs for either stand-alone or adjunct
cancer therapy.
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